Skip to content
Altius – Lifestyle
Author:
Sironax USA, Inc.
Sironax Announces Three Abstracts on SARM1 Inhibitor SIR2501 Selected for Presentation at Neuroscience 2026
October 29, 2026
Sironax Advances Enrollment in Phase 2 FORGE-LM Obesity Trial of NAMPT Activator SIR4156
October 13, 2026
Sironax Named to Fierce Biotech’s “Fierce 15” List of the Most Innovative and Promising Private Biotechs of 2026
October 5, 2026
Sironax Announces Option Exercise and Asset Purchase
September 16, 2026
Sironax’s SARM1 Inhibitor SIR2501 Granted FDA Fast Track Designation in Chemotherapy-induced Peripheral Neuropathy (CIPN)
May 11, 2026